Inderscience Publishers

The impact of open IP platforms on IP-strategy norms in life sciences

0
- By: ,

Courtesy of Inderscience Publishers

Abstract: In the biomedical field multiple stakeholders may collaboratively develop, package and build transactions around technology. This is often referred to as open innovation, open biotechnology or open source R&D. Intellectual Property (IP) and IP rights play important roles in collaborative platforms but little research has previously assessed the impact that such platforms exert on corporate IP-strategies. A case study was therefore conducted of the Innovative Medicines Initiative (IMI), CAMBIA Biological Open Source (BiOS) and the Medicines for Malaria Venture (MMV). Our results impact managerial decision-makers at pharmaceutical, biotech and agriscience companies intending to implement corporate open innovation and IP strategies.

Customer comments

No comments were found for The impact of open IP platforms on IP-strategy norms in life sciences. Be the first to comment!